Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus SOMOPHYLLIN CRT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus SOMOPHYLLIN CRT.
BRONKOSOL vs SOMOPHYLLIN-CRT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular cAMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Category C
Category C
Bronchodilator
Bronchodilator